R01HD105939
Project Grant
Overview
Grant Description
Pediatric COVID-19 Severity Dashboard During Delta Variant Circulation - Project Summary/Abstract
Pediatric COVID-19 is a major national and global public health problem. Pediatric COVID-19 cases have been increasing since mid-July 2021, coincident with the predominance of the Delta variant. During most of the pandemic, children have typically experienced milder COVID-19 illness severity than adults. However, SARS-CoV-2 causes two types of severe pediatric disease: acute COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C). Both acute COVID-19 and MIS-C can cause organ dysfunction and death.
Recently, individual pediatric health systems have reported increasing numbers of hospitalized patients who are positive for SARS-CoV-2 (July-August 2021). Because children under 12 are not yet eligible for SARS-CoV-2 vaccines and most are returning to in-person school this fall, they will be potentially more vulnerable to SARS-CoV-2 infection than in the past. However, it is not known if the Delta variant causes higher severity disease in children, as it does in adults. If it does, then increased transmission as children return to in-person school could cause demand for inpatient and intensive care unit (ICU) services at pediatric health systems to outstrip supply.
Second, granular national data are not readily available. The overall objective of this supplement is to make information about the trajectories of pediatric COVID-19 hospitalization rates and disease severity readily available for national-level decision-making. We will implement pipelines to analyze the trajectories of pediatric COVID-19 hospitalization rates and build an interactive pediatric COVID-19 severity dashboard for near-real-time tracking of the pediatric impact of the SARS-CoV-2 pandemic.
To do this, we will leverage the National COVID Cohort Collaborative (N3C), a resource developed with funding from the National Center for Advancing Translational Sciences (NCATS). N3C aggregates electronic health record (EHR) data from more than 60 U.S. centers. In our prior work, we have demonstrated our ability to analyze the granular multicenter EHR data in N3C, leverage state-of-the-art computational resources on the N3C platform, and implement analytic techniques similar to those in this proposal.
We will use these rich EHR data in N3C to accomplish the following specific aim:
1A) Visualize and test the trends of pediatric COVID-19 hospitalization rates and disease severity over time, and
1B) Design and build an interactive pediatric COVID-19 severity dashboard.
We have assembled an investigative team with a successful track record in the field and will work in partnership with NIH and N3C leadership to address this national and global health priority. We expect the results of this supplement proposal to have a powerful and immediate impact on the outcomes of children with COVID-19 and pediatric COVID-19 policy-making by decreasing the likelihood of overwhelmed U.S. pediatric health systems.
Pediatric COVID-19 is a major national and global public health problem. Pediatric COVID-19 cases have been increasing since mid-July 2021, coincident with the predominance of the Delta variant. During most of the pandemic, children have typically experienced milder COVID-19 illness severity than adults. However, SARS-CoV-2 causes two types of severe pediatric disease: acute COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C). Both acute COVID-19 and MIS-C can cause organ dysfunction and death.
Recently, individual pediatric health systems have reported increasing numbers of hospitalized patients who are positive for SARS-CoV-2 (July-August 2021). Because children under 12 are not yet eligible for SARS-CoV-2 vaccines and most are returning to in-person school this fall, they will be potentially more vulnerable to SARS-CoV-2 infection than in the past. However, it is not known if the Delta variant causes higher severity disease in children, as it does in adults. If it does, then increased transmission as children return to in-person school could cause demand for inpatient and intensive care unit (ICU) services at pediatric health systems to outstrip supply.
Second, granular national data are not readily available. The overall objective of this supplement is to make information about the trajectories of pediatric COVID-19 hospitalization rates and disease severity readily available for national-level decision-making. We will implement pipelines to analyze the trajectories of pediatric COVID-19 hospitalization rates and build an interactive pediatric COVID-19 severity dashboard for near-real-time tracking of the pediatric impact of the SARS-CoV-2 pandemic.
To do this, we will leverage the National COVID Cohort Collaborative (N3C), a resource developed with funding from the National Center for Advancing Translational Sciences (NCATS). N3C aggregates electronic health record (EHR) data from more than 60 U.S. centers. In our prior work, we have demonstrated our ability to analyze the granular multicenter EHR data in N3C, leverage state-of-the-art computational resources on the N3C platform, and implement analytic techniques similar to those in this proposal.
We will use these rich EHR data in N3C to accomplish the following specific aim:
1A) Visualize and test the trends of pediatric COVID-19 hospitalization rates and disease severity over time, and
1B) Design and build an interactive pediatric COVID-19 severity dashboard.
We have assembled an investigative team with a successful track record in the field and will work in partnership with NIH and N3C leadership to address this national and global health priority. We expect the results of this supplement proposal to have a powerful and immediate impact on the outcomes of children with COVID-19 and pediatric COVID-19 policy-making by decreasing the likelihood of overwhelmed U.S. pediatric health systems.
Funding Goals
TO CONDUCT AND SUPPORT LABORATORY RESEARCH, CLINICAL TRIALS, AND STUDIES WITH PEOPLE THAT EXPLORE HEALTH PROCESSES. NICHD RESEARCHERS EXAMINE GROWTH AND DEVELOPMENT, BIOLOGIC AND REPRODUCTIVE FUNCTIONS, BEHAVIOR PATTERNS, AND POPULATION DYNAMICS TO PROTECT AND MAINTAIN THE HEALTH OF ALL PEOPLE. TO EXAMINE THE IMPACT OF DISABILITIES, DISEASES, AND DEFECTS ON THE LIVES OF INDIVIDUALS. WITH THIS INFORMATION, THE NICHD HOPES TO RESTORE, INCREASE, AND MAXIMIZE THE CAPABILITIES OF PEOPLE AFFECTED BY DISEASE AND INJURY. TO SPONSOR TRAINING PROGRAMS FOR SCIENTISTS, DOCTORS, AND RESEARCHERS TO ENSURE THAT NICHD RESEARCH CAN CONTINUE. BY TRAINING THESE PROFESSIONALS IN THE LATEST RESEARCH METHODS AND TECHNOLOGIES, THE NICHD WILL BE ABLE TO CONDUCT ITS RESEARCH AND MAKE HEALTH RESEARCH PROGRESS UNTIL ALL CHILDREN, ADULTS, FAMILIES, AND POPULATIONS ENJOY GOOD HEALTH. THE MISSION OF THE NICHD IS TO ENSURE THAT EVERY PERSON IS BORN HEALTHY AND WANTED, THAT WOMEN SUFFER NO HARMFUL EFFECTS FROM REPRODUCTIVE PROCESSES, AND THAT ALL CHILDREN HAVE THE CHANCE TO ACHIEVE THEIR FULL POTENTIAL FOR HEALTHY AND PRODUCTIVE LIVES, FREE FROM DISEASE OR DISABILITY, AND TO ENSURE THE HEALTH, PRODUCTIVITY, INDEPENDENCE, AND WELL-BEING OF ALL PEOPLE THROUGH OPTIMAL REHABILITATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Colorado
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/25 to 05/31/30 and the total obligations have increased 417% from $754,556 to $3,901,596.
The Regents Of The Univ. Of Colorado was awarded
Pediatric COVID-19 Severity Dashboard: Delta Variant Impact Analysis
Project Grant R01HD105939
worth $3,901,596
from the National Institute of Child Health and Human Development in September 2021 with work to be completed primarily in Colorado United States.
The grant
has a duration of 8 years 8 months and
was awarded through assistance program 93.865 Child Health and Human Development Extramural Research.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 9/5/25
Period of Performance
9/22/21
Start Date
5/31/30
End Date
Funding Split
$3.9M
Federal Obligation
$0.0
Non-Federal Obligation
$3.9M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R01HD105939
Transaction History
Modifications to R01HD105939
Additional Detail
Award ID FAIN
R01HD105939
SAI Number
R01HD105939-2780163907
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NT00 NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development
Funding Office
75NT00 NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development
Awardee UEI
MW8JHK6ZYEX8
Awardee CAGE
0P6C1
Performance District
CO-90
Senators
Michael Bennet
John Hickenlooper
John Hickenlooper
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Institute of Child Health and Human Development, National Institutes of Health, Health and Human Services (075-0844) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,481,607 | 100% |
Modified: 9/5/25